Literature DB >> 19200788

Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome.

Xiaoli Liu1, Peizeng Yang, Xiaomin Lin, Xiangrong Ren, Hongyan Zhou, Xiangkun Huang, Wei Chi, Aize Kijlstra, Ling Chen.   

Abstract

Cyclosporin A (CsA) and corticosteroids are extensively used in the treatment of autoimmune diseases including Vogt-Koyanagi-Harada (VKH) syndrome. The exact immunosuppressive mechanisms of these drugs are not exactly known. Th1 and Th17 cells are important populations involved in autoimmune diseases. In this study, we investigated whether they are involved in VKH syndrome and how their function is affected by CsA and corticosteroids. The results showed that IL-17, IFN-gamma, RORgammat and T-bet were upregulated in patients with active uveitis. CsA and corticosteroids were able to downregulate all these elevated levels which correlated with the clinical improvement of the uveitis. In vitro experiments showed that CsA and dexamethasone could decrease the frequencies of Th1 and Th17 cells and inhibit IL-17 and IFN-gamma production. These data suggest that an upregulated Th1 and Th17 response is associated with active VKH syndrome. CsA and corticosteroids may exert their immunosuppressive role by downregulating Th1 and Th17 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200788     DOI: 10.1016/j.clim.2008.12.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  18 in total

1.  Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13.

Authors:  C S De Paiva; J K Raince; A J McClellan; K P Shanmugam; S B Pangelinan; E A Volpe; R M Corrales; W J Farley; D B Corry; D-Q Li; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2010-12-22       Impact factor: 7.313

2.  Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina.

Authors:  Verónica E Giordano; Ariel Schlaen; Martín J Guzmán-Sánchez; Cristobal Couto
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

3.  Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals.

Authors:  Chiharu Iwahashi; Kensuke Okuno; Noriyasu Hashida; Kei Nakai; Nobuyuki Ohguro; Kohji Nishida
Journal:  Jpn J Ophthalmol       Date:  2015-03-26       Impact factor: 2.447

4.  Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A.

Authors:  Wei Chi; Peizeng Yang; Xuefei Zhu; Yuqin Wang; Lina Chen; Xiangkun Huang; Xiaoli Liu
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

5.  Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.

Authors:  Cheng-bo Fang; De-xi Zhou; Shu-xiang Zhan; Yong He; Zhen Lin; Cheng Huang; Jun Li
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

6.  Label-free proteomics reveals decreased expression of CD18 and AKNA in peripheral CD4+ T cells from patients with Vogt-Koyanagi-Harada syndrome.

Authors:  Liming Mao; Peizeng Yang; Shengping Hou; Fuzhen Li; Aize Kijlstra
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

7.  Vogt-Koyanagi-Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells.

Authors:  M Bonacini; L Cimino; L De Simone; E Bolletta; F Gozzi; A Soriano; F Muratore; A Zerbini; L Fontana; C Salvarani; S Croci
Journal:  Clin Exp Immunol       Date:  2020-12-27       Impact factor: 5.732

8.  Decreased expression of the aryl hydrocarbon receptor in ocular Behcet's disease.

Authors:  Chaokui Wang; Zi Ye; Aize Kijlstra; Yan Zhou; Peizeng Yang
Journal:  Mediators Inflamm       Date:  2014-06-22       Impact factor: 4.711

Review 9.  miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.

Authors:  Fabian Vega-Tapia; Mario Bustamante; Rodrigo A Valenzuela; Cristhian A Urzua; Loreto Cuitino
Journal:  Front Cell Dev Biol       Date:  2021-05-10

10.  B cells contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls.

Authors:  Paul Martin Schlegel; Ingeborg Steiert; Ina Kötter; Claudia A Müller
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.